Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient

CAR-T–cell therapy normally requires the patient’s own healthy T cells. An allogeneic CAR-T bridging therapy could rescue lymphopenic patients.

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Zhang, Jian-Ping, Zhang, Rui, Tsao, Shih-Ting, Liu, Yu-Chen, Chen, Xiaochuan, Lu, Dao-Pei, Castillo, Paul, Chang, Lung-Ji
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Exceptional Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058233/
https://ncbi.nlm.nih.gov/pubmed/30026294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018017004
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki